Ikena Oncology Stock Today
| IKNA Stock | USD 1.69 0.02 1.17% |
Performance0 of 100
| Odds Of DistressOver 54
|
Ikena Oncology is trading at 1.69 as of the 28th of November 2024, a 1.17 percent decrease since the beginning of the trading day. The stock's open price was 1.71. Ikena Oncology has 54 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Ikena Oncology are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of December 2022 and ending today, the 28th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 26th of March 2021 | Category Healthcare | Classification Health Care |
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts. Ikena Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 48.26 M outstanding shares of which 129.88 K shares are currently shorted by private and institutional investors with about 1.39 trading days to cover. More on Ikena Oncology
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Ikena Stock Highlights
| CEO President | Mark Manfredi | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIkena Oncology can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ikena Oncology's financial leverage. It provides some insight into what part of Ikena Oncology's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Ikena Oncology (IKNA) is traded on NASDAQ Exchange in USA. It is located in 645 Summer Street, Boston, MA, United States, 02210 and employs 14 people. Ikena Oncology is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 82.52 M. Ikena Oncology conducts business under Biotechnology sector and is part of Health Care industry. The entity has 48.26 M outstanding shares of which 129.88 K shares are currently shorted by private and institutional investors with about 1.39 trading days to cover.
Ikena Oncology currently holds about 192.81 M in cash with (79.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Ikena Oncology Probability Of Bankruptcy
Ownership AllocationIkena Oncology has a total of 48.26 Million outstanding shares. Over half of Ikena Oncology's outstanding shares are owned by outside corporations. These outside corporations are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Ikena Ownership Details
Ikena Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Sofinnova Ventures | 2024-06-30 | 382.6 K | |
| Blackrock Inc | 2024-06-30 | 354.8 K | |
| Millennium Management Llc | 2024-06-30 | 354.7 K | |
| Goldman Sachs Group Inc | 2024-06-30 | 273.8 K | |
| Geode Capital Management, Llc | 2024-09-30 | 271 K | |
| Barclays Plc | 2024-06-30 | 196 K | |
| Two Sigma Advisers, Llc | 2024-06-30 | 173.2 K | |
| Citadel Advisors Llc | 2024-09-30 | 165 K | |
| Bridgeway Capital Management, Llc | 158.4 K | ||
| Bvf Inc | 2024-09-30 | 4.8 M | |
| Blue Owl Capital Holdings Lp | 2024-09-30 | 4.1 M |
Ikena Oncology Historical Income Statement
Ikena Stock Against Markets
Ikena Oncology Corporate Management
| Navin MS | VP Quality | Profile | |
| Sabine Ruppel | VP Discovery | Profile | |
| Jennifer Schroeder | Sr Operations | Profile | |
| Rebecca Cohen | Corporate Relations | Profile | |
| Valdas Jurkauskas | Senior Operations | Profile | |
| MBA MD | Chief Officer | Profile | |
| David MS | Senior Operations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ikena Oncology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Ikena Stock refer to our How to Trade Ikena Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ikena Oncology. If investors know Ikena will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ikena Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.23) | Revenue Per Share 0.014 | Quarterly Revenue Growth (0.88) | Return On Assets (0.22) | Return On Equity (0.37) |
The market value of Ikena Oncology is measured differently than its book value, which is the value of Ikena that is recorded on the company's balance sheet. Investors also form their own opinion of Ikena Oncology's value that differs from its market value or its book value, called intrinsic value, which is Ikena Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ikena Oncology's market value can be influenced by many factors that don't directly affect Ikena Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ikena Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ikena Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ikena Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.